Clinical trials: SCLC, Extensive Stage
SCLC, SCLC, Extensive Stage
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
- Conditions
- SCLC, SCLC, Extensive Stage, SCLC, Limited Stage, Small Cell Lung Cancer
- Trial name
- NCT07508852
- Testing
- Sequential [18F]-FDG PET/CT, [68Ga]Ga-PFD3 PET/CT scan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
SCLC, Extensive Stage
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment
This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.
- Trial name
- Aurora003 (NCT07632209)
- Testing
- Lomustine, Anlotinib
- Volunteers
- 46 people
- Sponsor
- Yayi He
SCLC,Extensive Stage, SLFN11-positive
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
RAISE is an international, multicentre, single-arm phase II trial. The trial treatment consists of the addition of niraparib, 200 mg orally once daily to anti-PD-L1 antibody maintenance.
- Trial name
- RAISE (NCT05718323)
- Testing
- Niraparib
- Where
- 18 sites in France, Germany and 3 more
- Volunteers
- 44 people
- Sponsor
- ETOP IBCSG Partners Foundation
SCLC, Extensive Stage
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients…
- Trial name
- NCT06812260
- Testing
- HLX10+chemo
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Shanghai Henlius Biotech
Small Cell Lung Cancer, SCLC
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's…
- Conditions
- Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer, Limited Stage Small-Cell Lung Cancer
- Trial name
- MOZART (NCT05903092)
- Testing
- Durvalumab, Monalizumab, Carboplatin or Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Hirva Mamdani
SCLC, Extensive Stage
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Phase Ib/II, open-label, multicentre study to evaluate the efficacy and safety of low-dose radiotherapy (LDRT) combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC.
- Trial name
- NCT06477523
- Testing
- AK104, Etoposide, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Sichuan University
Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
This is a prospective, single-arm, investigator-initiated clinical study (IIT) designed to evaluate the efficacy and safety of nab-paclitaxel combined with local radiotherapy for patients with extensive-stage small cell lung…
- Trial name
- NCT07547332
- Testing
- Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Volunteers
- 84 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
SCLC, Extensive Stage
A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer
This is a single-center, single-arm, exploratory clinical study conducted at Shanghai Pulmonary Hospital, Tongji University. It aims to evaluate the efficacy and safety of first-line treatment with benmelstobart plus anlotinib…
- Trial name
- Aurora 005 (NCT07538271)
- Testing
- benmelstobart, Anlotinib, Carboplatin or cisplatin
- Volunteers
- 33 people
- Sponsor
- Yayi He
SCLC,Extensive Stage
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated…
- Trial name
- NCT05595460
- Testing
- RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- RayzeBio, Inc.
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This is an single-arm, multicenter phase II study to evaluate the safety and efficacy of Sacituzumab Tirumotecan (sac-TMT) plus anlotinib in previously treated extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- STAR-01 (NCT07501169)
- Testing
- Sacituzumab Tirumotecan and Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sichuan University
SCLC, Extensive Stage
Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Small Cell Lung cancer (SCLC) is a highly aggressive tumor that accounts for about 15 percent of all lung cancer cases. SCLC disease progresses rapidly, and about 2/3 of the patients have extensive stage (ES-SCLC) at the time of…
- Trial name
- NCT04660097
- Testing
- Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, SCLC, Extensive Stage
- Trial name
- DART-NK-SCLC (NCT07480213)
- Testing
- EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
SCLC, SCLC, Extensive Stage
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC
This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- JACKPOT38 (NCT07110103)
- Testing
- golidocitinib with PD-1 inhibitors
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
This study is a prospective, single arm, phase II clinical trial. We plan to include 36 newly diagnosed ES-SCLC patients who meet the inclusion criteria and receive induction therapy (tislelizumab+EP regimen, 4-6 cycles).
- Trial name
- NCT07425795
- Testing
- Tislelizumab Combined With Chemotherapy
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing University Cancer Hospital
SCLC, Extensive Stage
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
This is a phase I study to evaluate the safety and preliminary efficacy of [225Ac]Ac-DOTATATE injection combined with tislelizumab in the maintenance treatment period for patients of extensive-stage small cell lung cancer…
- Trial name
- NCT07413042
- Testing
- [225Ac]Ac-DOTATATE
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Peking University Cancer Hospital & Institute
NSCLC (Advanced Non-small Cell Lung Cancer), SCLC, Extensive Stage
Anlotinib in Cross-line Treatment of NSCLC and SCLC
Previous studies on bevacizumab in colorectal and ovarian cancers have demonstrated that continued anti-angiogenic therapy after disease progression can still provide clinical benefits.
- Trial name
- NSCLC SCLC (NCT07400575)
- Volunteers
- 350 people
- Sponsor
- Henan Cancer Hospital
Extensive-stage Small Cell Lung Cancer (SCLC)
YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
Globally, lung cancer stands as the foremost cause of cancer-related mortality. Among its subtypes, small cell lung cancer (SCLC) represents an exceptionally aggressive malignancy, accounting for approximately 15-20% of all lung…
- Trial name
- NCT07390565
- Testing
- Yishen Qutong Granules, Yishen Qutong Simulant Granules
- Where
- China
- Volunteers
- 308 people
- Sponsor
- LI FENG
SCLC, Extensive Stage, Advanced Solid Tumors
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, multi-cohort investigation exploring the efficacy and safety of ABP1011T tablets in participants with specific target solid tumors, providing a foundation for subsequent clinical research.
- Trial name
- ABP1011T-03 (NCT07321574)
- Testing
- ABP1011T
- Where
- 8 sites in China
- Volunteers
- 110 people
- Sponsor
- Shanghai AB PharmaTech Ltd.
SCLC,Extensive Stage
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
This prospective clinical study aims to evaluate and observe the efficacy and safety of adebrelimab combined with etoposide capsules in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial…
- Trial name
- NCT07141264
- Testing
- Adebrelimab combined with Etoposide Capsules
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Tang-Du Hospital
SCLC, Extensive Stage, Toripalimab
Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer
This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer…
- Trial name
- NCT07308379
- Testing
- Toripalimab
- Volunteers
- 1,200 people
- Sponsor
- Fudan University